| Literature DB >> 22617227 |
R A Wilke1, L B Ramsey, S G Johnson, W D Maxwell, H L McLeod, D Voora, R M Krauss, D M Roden, Q Feng, R M Cooper-Dehoff, L Gong, T E Klein, M Wadelius, M Niemi.
Abstract
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22617227 PMCID： PMC3384438 DOI： 10.1038/clpt.2012.57
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875